175 MS activists are heading to Washington, D.C. next week for the National MS Society's Public Policy Conference. Their mission: to bring the concerns of the MS community directly to lawmakers on Capitol Hill.

When it comes to the legislative support for healthcare and medical research, it's no secret that these are unusual times. Joining me to brief us on the National MS Society's ongoing advocacy efforts and give us a sneak peek at the specific legislative issues we'll be taking to Capitol Hill is the National MS Society's Vice President of Advocacy, Steffany Stern.

We'll also share updated results from an important study that show the risk of developing MS if a close relative is living with the disease is significantly higher than researchers originally thought.

And we'll give you all the details of a Phase 1 clinical trial that's focused on a novel approach to CAR-T cell therapy for MS.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: Preparing for the MS Society's Public Policy Conference :22

I'm asking for your support: 1:37

An update to a 2015 study shows close relatives of people living with MS are 100 times more likely than the general population to develop MS 2:15

A novel approach to CAR-T cell therapy for MS is recruiting for a Phase 1 clinical trial 4:26

Steffany Stern, the Vice President of Research at the National MS Society, shares a major advocacy win and previews next week's Public Policy Conference in Washington, D.C. 7:27

Share this episode 33:04

Next week 33:25

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/446

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected] Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Support Jon at WALK MS https://realtalkms.com/walkms

JOIN: Become an MS Activist https://nationalmssociety.org/advocacy

STUDY: A Prospective Study of Individuals at Risk of Multiple Sclerosis Informs the Design of Primary Prevention Studies https://onlinelibrary.wiley.com/doi/10.1002/acn3.70340

GEMS Study Recruitment https:/nationalmssociety.org/news-and-magazine/news/ms-study-alert-gems

RealTalk MS Ep. 439: Preventing MS with Dr. Bruce Bebo https://realtalkms.com/439

PARTICIPATE: A Study to Assess the Safety and Clinical of Azer-cel in Participants with B-cell Mediated Autoimmune Disorders https://clinicaltrials.gov/study/NCT06680037/#contacts-and-locations

JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 446 Guests: Steffany Stern

Privacy Policy

It's MS Awareness Week, and this year we're diving into a theme that hits home for millions: Unseen MS. Multiple sclerosis is a master of disguise; it can be entirely invisible to the naked eye while remaining profoundly life-altering for the person living it.

In this episode, we're exploring the spectrum of the MS experience through two distinct, yet deeply connected stories.

First, you'll hear from RealTalk MS team member Kristine Werner Ozug. Kristine shares what it's like to navigate a world that doesn't always see her struggle, and how her "mostly invisible" MS symptoms still dictate the rhythm of her daily life.

Then, you'll meet the two Kims (and a third). Kim W and Kim P, have been together for 16 years. They both live with MS—but in very different ways. While Kim P has navigated RRMS for 18 years with largely invisible symptoms, Kim W was diagnosed with PPMS just three years ago and faces much more visible physical challenges.

Joining our conversation with Kim and Kim is Kim Fredsall, a physical therapist at Gaylord Specialty Healthcare, who provides expert context on bridging the gap between diagnosis and daily management.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: It's MS Awareness Week :22

Kristine Werner Ozug shares her story 1:24

Kim W. and Kim P. share their story 24:49

Share this episode 39:14

Next week 39:34

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/445

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected] Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Support Jon at WALK MS https://realtalkms.com/walkms

JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 445 Guests: Kristine Werner Ozug, Kim P, Kim W, and Kim Fredsall

Privacy Policy

You know them by their trade names such as Ozempic, Wegovy, Mounjaro, and Zepbound. This class of medications is known as GLP-1 receptor agonists. And while they are best known for managing diabetes and promoting weight loss, researchers are finding that these drugs are also effective in a broad range of other health conditions. So, what about MS?

My guest this week is Dr. Ellen Mowry, the principal investigator of a clinical trial to determine whether a GLP-1 drug can reduce brain inflammation and provide neuroprotection in people living with progressive MS.

We're sharing details about the discovery of a new biomarker that not only confirms an MS diagnosis but also predicts the severity of an individual's disease course in the years ahead.

We'll tell you about three studies focused on better managing some of the most common MS symptoms and funded by the International Progressive MS Alliance.

And we'll explain how Merck and the Mayo Clinic are partnering to build a first-of-its-kind drug discovery platform using AI.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: A GLP-1 for MS? :22

I'm asking for your support: 1:31

Researchers discover biomarkers that can predict future disease course 2:13

The International Progressive MS Alliance invests $8.1 million in global studies that address the most common MS symptoms 5:44

Merck and the Mayo Clinic collaborate on AI-driven drug discovery platform 10:02

Dr. Ellen Mowry discusses the clinical trial to determine whether a GLP-1 drug can reduce inflammation in the central nervous system and offer neuroprotection to people with progressive MS 12:20

Share this episode 30:17

Next week 30:38

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/444

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected] Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Support Jon at WALK MS https://realtalkms.com/walkms

STUDY: Large-Scale Proteomics Across Neurological Disorders Uncovers Biomarker Panel and Targets in Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/41747728

International Progressive MS Alliance https://progressivemsalliance.org

JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 444 Guests: Dr. Ellen Mowry

Privacy Policy

Welcome back to the third and final part of our coverage of the 2026 ACTRIMS Forum. This week's episode bridges the gap between groundbreaking clinical research and the nuanced reality of living with MS every day.

First, we'll dive into the "before" and "after" of a diagnosis, starting with Dr. Helen Tremlett's insights into the MS prodrome—those subtle, early signs that appear years before typical MS symptoms. We'll also talk with Dr. Tremlett about how other health conditions can predict long-term outcomes in sometimes surprising ways.

Dr. Ilana Katz Sand shares her latest research on the connection between diet, MRI findings, and clinical disability. Dr. Katz Sand also shares her list of foods you want to include and those you need to exclude when you choose the MIND diet. And Dr. Katz Sand explains the complementary roles of lifestyle choices and disease-modifying therapies in creating the most effective MS treatment plan.

Finally, we ground these scientific advancements in the lived experience as Kathy Smith joins us to challenge the clinical labels we use to describe MS, questioning whether terms like "relapsing-remitting" or "secondary-progressive" truly capture the day-to-day reality of her two-decade journey with the disease.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: The 2026 ACTRIMS Forum (Part 3) :22

Dr. Helen Tremlett discusses the prodromal phase of MS, which comorbidities are predictive of better or worse patient outcomes, and the role of the environment in pediatric MS 1:19

Dr. Ilana Katz Sand shares her latest research on the impact of diet on MS 10:44

As someone who has lived with MS for two decades, Kathy Smith takes on the question of whether the current labels like 'relapsing-remitting' or 'secondary-progressive' actually describe what life is like on a day-to-day basis for someone living with MS 22:35

Share this episode 34:29

Next week's episode 34:49

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/443

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected] Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Support Jon at WALK MS https://realtalkms.com/walkms

Find out about ABLEnow Accounts https://ablenow.com

JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 443 Guests: Dr. Helen Tremlett, Dr. Ilana Katz Sand, and Kathy Smith

Privacy Policy

Welcome back to Part Two of our coverage of the 2026 ACTRIMS Forum. This week, we shift our focus to emerging therapies and clinical insights that are re-shaping the future of MS care. From the latest information on stem cell transplantation to evolving treatment strategies to the labels used to describe MS, we're breaking down the complex science into the conversations that matter most to the MS community.

Joining me to discuss one of the most significant presentations from the 2026 ACTRIMS Forum is Dr. Jeffrey Cohen, who opened the event with the Kenneth P. Johnson Memorial Lecture.

Dr. Cohen's lecture, "AHSCT: Current Status and Remaining Questions," tackled a topic of massive interest to both clinicians and the MS community: Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Often described as "resetting" the immune system, AHSCT is a complex and life-changing procedure that continues to evolve.

In our conversation, Dr. Cohen delves deeper into his lecture, discussing transplant efficacy, the best candidates for AHSCT, the optimal time to consider AHSCT, and how people living with MS may qualify to participate in a clinical trial comparing the benefits of AHSCT with those of high-efficacy disease-modifying therapies.

Joining me for a deep dive into the future of MS care is Dr. Daniel Ontaneda. Our wide-ranging conversation explores the cutting edge of clinical practice and research, including the "early vs aggressive" treatment debate, how incorporating new imaging biomarkers will lead to faster, more reliable, and more accurate MS diagnoses, and whether the current disease classifications still serve the best interests of patient care.

While MS research conferences like the ACTRIMS Forum are never short on world-class expert opinions and groundbreaking data, one perspective is often missing from the room: the voice of someone living with the disease.

That's why I was so glad to have Kristine Werner Ozug, a valued member of the RealTalk MS team, on the ground with me. As someone living with MS, Kristine brings a vital lens to these scientific sessions. After the final gavel fell, I sat down with her to get her "patient-first" perspective on the research that mattered most to her and what she's taking away from this year's Forum.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: The 2026 ACTRIMS Forum (Part 2) :22

Dr. Jeffrey Cohen takes us on a deep-dive into Autologous Hematopoietic Stem Cell Transplantation (AHSCT) 1:23

Dr. Daniel Ontaneda discusses the ways that today's MS research will impact tomorrow's MS care 10:44

Kristine Werner Ozug shares her "patient-first" perspective on the research that mattered most to her and what she's taking away from the 2026 ACTRIMS Forum 28:17

Share this episode 43:31

Next week's episode 43:54

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/442

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected] Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Support Jon at WALK MS https://realtalkms.com/walkms

Find out about ABLEnow Accounts https://ablenow.com

JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 442 Guests: Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug

Privacy Policy

Last week, over 1,400 scientists and clinicians gathered in San Diego, California, at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting, better known as the ACTRIMS Forum. This week, in Part One of our coverage, you'll hear from three of the experts who presented their research at the ACTRIMS Forum.

Dr. Manuel Friese, a clinician-scientist at the Institute of Neuroimmunology and Multiple Sclerosis at the University Medical Center Hamburg-Eppendorf in Hamburg, Germany, where he serves as the Director of the Center for Molecular Neurobiology, and the Director of the Institute of Neuroimmunology and Multiple Sclerosis, is this year's winner of the Barancik Prize for Innovation in Multiple Sclerosis. I had an opportunity to talk with Dr. Friese about some of his truly remarkable research.

Dr. Amit Bar-Or, the Director of the Centre for Neuroinflammation and Experimental Therapeutics (CNET) and Chief of the Division of Multiple Sclerosis (MS) and related disorders at the University of Pennsylvania, presented encouraging results from two important clinical trials. Dr. Bar-Or and I discussed what those results might mean for people living with relapsing-remitting and primary progressive MS.

Dr. Haritha Desu, a young investigator at the ACTRIMS Forum, presented her cutting-edge research on how immune cells interact with cells already resident in the brain to drive damage or potentially promote repair. I talked with Dr. Desu about how her work could be key to stopping MS progression independent of relapse activity.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: The 2026 ACTRIMS Forum :22

Barancik Prize winner Dr. Manuel Friese discusses his pioneering discoveries 1:34

Dr. Amit Bar-Or shares encouraging results from two important clinical trials 16:27

Dr. Haritha Desu discusses her research 25:27

Share this episode 32:23

Next week's episode 32:42

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/441

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected] Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Support Jon at WALK MS https://realtalkms.com/walkms

Find out about ABLEnow Accounts https://ablenow.com

JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 441 Guests: Dr. Manuel Friese, Dr. Amit Bar-Or, and Dr. Haritha Desu

Privacy Policy

This past December, the FDA issued a Complete Response Letter to drug manufacturer Sanofi in response to Sanofi's application seeking approval for Tolebrutinib, the first in a new category of investigational disease-modifying therapies to undergo FDA review. A Complete Response Letter is an official letter from the FDA to a drug manufacturer stating that the agency can't approve a new medicine in its current form. It's not an outright "no" that kills a project; it's more like a "not yet." However, this Complete Response Letter raised some issues which, at first glance, don't appear to be easily fixable.

Sanofi has pointed out that the issues raised in the Complete Response Letter were markedly different from the guidance they received from the FDA over the course of this approval process. Sanofi has also indicated that it would work with the FDA to find a path forward for Tolebrutinib.

Dr. William Conte, an MS Specialist and a principal investigator in the Phase 3 clinical trial for Tolebrutinib, has published an article responding to the FDA's Complete Response Letter. This week, Dr. Conte joins me to discuss the FDA's action and his response to that action.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: We're at the 2026 ACTRIMS Forum :22

Check out the official ACTRIMS Forum Insider podcast! :42

The FDA's Complete Response Letter about Tolebrutinib 1:09

Dr. William Conte responds to the FDA's Complete Response Letter 4:09

Share this episode 38:10

Next week's episode 38:30

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/440

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected] Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Support Jon at WALK MS https://realtalkms.com/walkms

Find out about ABLEnow Accounts https://ablenow.com

JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 440 Guests: Dr. William Conte

Privacy Policy

The first coordinated global research strategy to prevent MS has been announced. This week, Dr. Bruce Bebo, the National MS Society's Executive Vice President and Chief Research & Medical Affairs Officer, joins me to explain what MS prevention looks like and how experts plan to achieve this remarkable goal.

We'll also tell you who won the 2025 Barancik Prize for Innovation in MS Research, and we'll explain how their groundbreaking research impacts MS care.

We're sharing the details of a newly announced partnership designed to reduce delays in getting an MS diagnosis and expand access to MS care in Wisconsin.

We'll tell you how an international drug discovery network found that a drug already approved for another condition could also protect nerve cells and promote remyelination.

And we'll share research that shows that AI can accurately predict whether someone newly diagnosed with MS will experience progression independent of relapse activity (PIRA) in the three years following their diagnosis.

We have a lot to talk about! Are you ready for RealTalk MS??!

I'm asking for your support: :22

This Week: Preventing MS 1:47

Dr. Manuel Friese is the winner of the 2025 Barancik Prize for Innovation in MS Research 2:41

National MS Society announces a partnership to improve time to MS diagnosis and access to MS care in Wisconsin 6:26

An international drug discovery network identifies a drug that protects nerve cells and promotes remyelination 8:05

STUDY: AI accurately predicts progression independent of relapse activity in individuals who are newly diagnosed with MS 10:51

Dr. Bruce Bebo explains the strategy behind the global research initiative to prevent MS 14:48

Share this episode 31:31

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/439

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected] Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Support Jon at WALK MS https://realtalkms.com/walkms

RealTalk MS Episode 424: I'm a Participant in a Clinical Trial for CAR T-Cell Therapy for MS with Jan Janisch-Hanzlik https://realtalkms.com/424

STUDY: In Silico Screening and Preclinical Validation Identify Bavisant as a Therapeutic Candidate for Multiple Sclerosis https://science.org/doi/10.1126/scitranslmed.ads0633

STUDY: Machine Learning Analysis Applied to Prediction of Early Progression Independent of Relapse Activity in Multiple Sclerosis Patients https://onlinelibrary.wiley.com/doi/10.1111/ene.70417

Find out about ABLEnow Accounts https://ablenow.com

JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 439 Guests: Dr. Bruce Bebo

Privacy Policy

One of the more confusing aspects of MS is that it can present differently from one person to the next. A research team at University College London may have uncovered a reason for that when they identified two new, and quite different, subtypes of MS.

Joining me to walk us through this discovery and to explain how it may impact MS clinical care is the study's principal investigator, Dr. Arman Eshaghi.

We're also sharing study results that may explain how the Epstein-Barr Virus triggers MS in some individuals.

We'll tell you about the free online fitness and wellness programs for veterans living with MS offered by the Paralyzed Veterans of America.

And we'll explain how the latest entrant in the AI for healthcare revolution can prepare you for your next appointment with your neurologist.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: Discovering 2 new subtypes of MS :22

Study results show how the Epstein-Barr Virus may trigger MS 1:20

The PVA is offering free online fitness and wellness classes for veterans with MS 5:45

Claude for Healthcare joins the AI in healthcare revolution 7:03

Dr. Arman Eshaghi discusses his team's discovery of 2 subtypes of MS 9:59

Share this episode 28:15

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/438

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected] Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

EBV Infection and HLA-DR15 Jointly Drive Multiple Sclerosis by Myelin Peptide Presentation https://www.cell.com/cell/fulltext/S0092-8674(25)01495-3

STUDY: Combined Magnetic Resonance Imaging and Serum Analysis Reveals Distinct Multiple Sclerosis Types https://academic.oup.com/brain/article/148/12/4578/8321558

PVA Offers Free Online Fitness & Wellness Classes for Vets with MS https://pva.org/sports-recreation/online-programs

Find out about ABLEnow Accounts https://ablenow.com

Claude for Healthcare https://claude.com/solutions/healthcare

JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 438 Guests: Dr. Arman Eshaghi

Privacy Policy

I don't have to remind anyone who listens to this podcast that the cost of MS disease-modifying therapies is obscenely high. And we're not just talking about relatively new medications. Older medications -- some decades old -- continue to increase in price without any rational explanation for why or how. On January 2nd, we lost a true warrior in the ongoing battle to lower the price of prescription drugs when David Mitchell, the founder of Patients for Affordable Drugs, passed away.

I met David in 2018 at a National MS Society Public Policy Conference, and he was a guest on Episode 31 of RealTalk MS. This week, I'm re-sharing the conversation we had in 2018.

We'll also tell you about an international workshop that represents the initial steps in developing a global research agenda to end MS.

We're explaining how AI is about to have a major impact on healthcare.

And we'll share the American Medical Association's brief to Congress, making the case for extending access to telehealth.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: We're remembering David Mitchell :22

The first steps toward a global research agenda to prevent MS were just published 1:02

Doctor AI will see you now 5:45

The American Medical Association asks lawmakers to extend access to telehealth 10:27

David Mitchell in his own words 12:41

Share this episode 27:56

Next week 28:16

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/437

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected] Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Patients for Affordable Drugs https://patientsforaffordabledrugs.org

PAPER: Toward a Global Research Agenda for Preventing Multiple Sclerosis https://journals.sagepub.com/doi/10.1177/13524585251398381

AMA BRIEF: The Case for Permanent Telehealth Policy and Expanded Access to Virtual Care https://ama-assn.org/system/files/issue-brief-telehealth-policy-expanded-access-to-virtual-care.pdf

ChatGPT Health https://openai.com/index/introducing-chatgpt-health

JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 437 Guests: David Mitchell

Privacy Policy

Scientists are expanding our understanding of MS at an unprecedented pace. This week, Dr. Leorah Freeman discusses why, as new discoveries and medications enter clinical practice, neurologists and MS specialists should ask themselves 3 important questions when considering a patient's treatment plan.

Dr. Freeman is the Director of the Multiple Sclerosis and Neuroimmunology Center at Dell Medical School at the University of Texas at Austin, where she also leads the MS and Neuroimmunology fellowship program and the MS Imaging and Outcomes Research Laboratory.

We'll also tell you about study results that reveal two distinct biologically-informed MS subtypes.

We're explaining some of the confusing background to the FDA's decision not to approve a disease-modifying therapy that achieved positive results in its Phase 3 clinical trial.

And did we really need a study to tell us that people living with MS fear experiencing a relapse or disease progression? Well, yes. We'll explain why.

We're also reminding you to mail your insurance premium payments and other important documents earlier than you have in the past.

And we're sharing details about the two clinical trials that received $4.1 million in funding as part of the International Progressive MS Alliance Experimental Medicine Trial Awards.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: 3 questions your neurologist should be asking themselves :22

Public Service Announcement: How the new rule about postmarks could affect your healthcare 1:16

FDA says it's not ready to approve Tolebrutinib 3:16

Study identifies two biologically-informed MS subtypes 6:29

Study results remind us that people with MS fear relapse and progression 10:09

The International Progressive MS Alliance invests $4.1 million in two clinical trials 14:04

Dr. Leorah Freeman discusses why neurologists need to ask themselves 3 important questions when considering a patient's treatment plan 17:18

Share this episode 33:16

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/436

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: [email protected] Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

The Multiple Sclerosis Insider https://themultiplesclerosisinsider.substack.com

STUDY: Combined Magnetic Resonance Imaging and Serum Analysis Reveals Distinct Multiple Sclerosis Types https://academic.oup.com/brain/article/148/12/4578/8321558

STUDY: Fear of Disease Progression and Relapse in Multiple Sclerosis: A Systematic Scoping Review https://frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1680781/full

JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 436 Guests: Dr. Leorah Freeman

Privacy Policy